Comparative Pharmacology
Head-to-head clinical analysis: SYNTHROID versus THYROLAR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNTHROID versus THYROLAR 5.
SYNTHROID vs THYROLAR-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic levothyroxine is a replacement for endogenous thyroid hormone. It binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
Thyrolar-5 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to T3 in peripheral tissues. T3 binds to thyroid hormone receptors, regulating gene transcription and increasing cellular metabolism.
Initial adult dose 1.6 mcg/kg orally once daily, adjusted by 12.5-25 mcg increments every 6-8 weeks based on TSH levels. Maintenance dose typically 100-125 mcg/day.
Oral, starting dose 15-30 mg daily, titrated to maintenance dose of 60-120 mg daily, divided into 2-3 doses.
None Documented
None Documented
Levothyroxine (T4) terminal elimination half-life: 6-7 days in euthyroid patients; shortened to 3-4 days in hyperthyroidism and prolonged to 9-10 days in hypothyroidism; clinical context: supports once-daily dosing with steady-state reached after 6-8 weeks.
Liothyronine (T3): 1-2 days; Levothyroxine (T4): 6-7 days. Clinical context: In hyperthyroidism, T4 half-life shortens to 3-4 days; in hypothyroidism, prolongs to 9-10 days
Renal: ~20-40% of T4 and T3 metabolites excreted in urine as glucuronide and sulfate conjugates; fecal: ~40-60% as unchanged drug and conjugates via biliary elimination; minor amounts in bile and feces as deiodinated products.
Renal: 40-50% (as conjugated metabolites); Fecal: 20-30% (enterohepatic recirculation); Biliary: minor
Category C
Category C
Thyroid Hormone
Thyroid Hormone